A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult V Olunteers
Latest Information Update: 13 Dec 2019
Price :
$35 *
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Advagene Biopharma
- 04 Dec 2019 Results assessing the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh published in the Vaccine
- 02 Jan 2019 New trial record